About US
Contact us
-
FDA approves paediatric LEMS drugThe US Food and Drug Administration (FDA) has approved Jacobus Pharmaceutical’s Ruzurgi (amifampridine) as a treatment for Lambert-Eaton myasthenic syndrome (LEMS). Ruzurgi is one of the first LEMS d2019/5/9
-
Bicycle and DDF collaborate on drug development for CNS conditionsUK-headquartered Bicycle Therapeutics and venture capital fund Dementia Discovery Fund (DDF) have entered into a collaboration to use the former’s bicyclic peptide technology to identify new targets2019/5/8
-
FDA approves Pfizer’s drugs for transthyretin amyloid cardiomyopathyThe US Food and Drug Administration (FDA) has approved Pfizer’s Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) to treat cardiomyopathy caused by transthyretin-mediated amyloidosis (ATTR-CM).2019/5/8
-
GSK chases Trelegy asthma nod with mixed phase 3 resultsWith generics attacking Advair, GlaxoSmithKline has talked up prospects for 3-in-1 respiratory med Trelegy. Now, the company has data in hand that could help it move into the asthma arena—though it's2019/5/7
-
Novo's fast-launching Ozempic puts Lilly on notice—and its GLP-1 pill is on its wayNovo Nordisk has been fighting head-to-head with Eli Lilly for share in the GLP-1 diabetes market—and losing, as Lilly's weekly Trulicity stole scripts from Novo's daily Victoza. But now that Novo ha2019/5/7
-
J&J eyes prostate cancer boost as FDA accepts Erleada for real-time reviewJohnson & Johnson has fallen behind the Pfizer-Astellas team with Erleada in the drug’s first approved indication. But now it looks poised to bring in another. The FDAacceptedthe New Jersey drugm2019/5/6
-
New Gilead chief plots Kite CEO hire, pipeline M&A and organizational tweaksGilead Sciences tapped new CEO Daniel O’Day in part because of his cancer expertise. But he’s not planning to lead the company’s oncology ramp-up alone. The Roche veteran intends to bring on a CEO fo2019/5/6
-
Endo CEO Campanelli nabs almost $20M in 2018 pay, thanks to special 2017 bonusEndo’s stock price hasn’t at all recovered from a sharp decline thanks to generics price erosion and a gloomy outlook for the company’s business. But CEO Paul Campanelli snagged a huge pay pump in 202019/5/5
-
Indivior slashes sales projections almost in half after $3B federal indictmentWith a $3 billion lawsuit from the U.S. government hanging overhead and Suboxone generics on the march, things are looking grim for Indivior. And executives warned Thursday that sales will take a big2019/5/5
-
Roche's Tecentriq-Avastin lung cancer combo gets a lift from England's cost watchdogsRoche has some hard-earned knowledge about working with England’s cost watchdogs, especially where its cancer drugs are concerned. And it put that know-how to use to score backing for Tecentriq in lu2019/4/30